Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

BACKGROUND: The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. CONCLUSIONS: A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence.
• 2 The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
• 3 METHODS: We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: